Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 10506—10516
Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin
Figure 6. Angiopep-2 polypeptide-modified and doxorubicin-loaded graphene oxide (ANG-Dox-GO) exhibited better anti-tumor effect of glioma xenograft mice. (A) The tumor volumes of mice with different treatments, including PBS (control), Dox (2 mg/kg), Dox-GO (containing 2 mg/kg of Dox), and ANG-Dox-GO (containing 2 mg/kg of Dox), respectively, every two days for 20 days. (B) The tumor weights of mice with different treatments, including PBS (control), Dox (2 mg/kg), Dox-GO (containing 2 mg/kg of Dox), and ANG-Dox-GO (containing 2 mg/kg of Dox), respectively, on 20 days. *P < 0.05.